Evaluate Omnium: An Award-Winning Decision
Evaluate Omnium is now officially an award-winning solution! Last month, we were delighted to announce that we have won an award. Evaluate Omnium, our machine learning-powered solution was named as Best Decision Management Solution by the AI Breakthrough awards. While we have always been very proud of Evaluate Omnium, and while we know that […]
BioSci Deal of the Month – Kite & Arcellx
In December of 2022, Kite and Arcellx entered an agreement to develop and commercialise Arcellx’s multiple myeloma product candidate CART-ddBCMA. The candidate is currently in Phase 2 clinical development and is a cell therapy product comprising of genetically modified autologous T cells. The collaboration brings together Arcellx’s promising CART-ddBCMA therapy with Kite’s expertise and leadership […]
Five Top Takeaways from BIO International 2023
A couple of weeks ago, we saw the return of BIO International to Boston for the first time since 2018. Since Boston is Evaluate’s home turf in the US, we headed to the gigantic Boston Convention Center to join 19,000 pharma, biotech and investment experts for four days of meetings, presentations, networking shindigs and sore […]
In Case You Missed It: Three Things We Learned In Our Gene Editing Webinar
Missed our gene editing webinar? Fear not! Here are a few of the highlights from our panel of experts which included Verve Therapeutics’ CEO, Sekar Kathiresan as well as our home-grown specialists. And if that’s not enough, the webinar is available on demand. Gene editing is a hot topic right now. With the first Pdufa […]
Five Questions About the Future of Gene Editing
Gene editing has been in and out of the news since Crispr hit the headlines a decade ago. It’s been anything from the next big thing to a borderline miracle to a potential menace. Is it just going through the same growing pains as any new technology in the pharma industry? Or is it fundamentally […]
BioSci Deal of the Month – Spero Therapeutics & GSK
In September of 2022, GSK and Spero Therapeutics entered into an exclusive license agreement for late-stage antibiotic asset, Tebipenem HBr. Tebipenem HBr is an oral carbapenem antibiotic aimed at treating complicated urinary tract infections including pyelonephritis. GSK will receive an exclusive license to develop and commercialise Tebipenem pivoxil and tebipenem pivoxil HBr in all territories […]
In Case You Missed It: Three Things We Learned From Our Orphan Drug Webinar
Missed our webinar on orphan drugs and the impact of the Inflation Reduction Act? Well, you missed a lot but here are a few takeaways to help you catch up. And the full webinar is available on demand. Drugs for orphan indications are a fascinating area of the pharma industry. Our recent report on the […]
BioSci Deal of the Month – Kainos Medicines & Emmaus Life Sciences
In February of 2021, Emmaus Life Sciences and Kainos Medicine entered into an agreement to jointly develop Kainos’ patented IRAK4 inhibitor (KM10544). IRAK4 is a serine-threonine protein kinase known to be present and active in the occurrence of certain immunity responses, inflammation disorders, and various cancers. Under the terms of this agreement, Kainos will study […]
It’s All About Impact: Why Orphan Drugs are a Big Deal for Patients and Pipelines
300 million people worldwide are living with a rare disease. The “orphan” drugs created to treat them have been a fast-growing part of the pharma market for years – and their use is often high profile. Every now and then a relative niche of the pharma world hits the mainstream – orphan drugs. It happened […]
Meet the Evaluate Team: Tom Moore
It’s Meet the Team time again and to kick off 2023 we’re hopping across the pond to meet one of our US-based team members, Tom Moore, SVP Account Management – Americas. Tom’s worked at Evaluate since the beginning of time (roughly) but he’s disappointingly discreet when it comes to shedding light on any skeletons in […]
